NCT04198558View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

Chronic Pain

Interventions

DRUG

MEDI0618

MEDI0618 A novel human immunoglobulin antibody

DRUG

Placebo

Placebo

Trial Locations (1)

10117

Research Site, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY